Results 201 to 210 of about 405,002 (265)

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Astrocytoma-Specific Prognostic Associations of Amyloid-Related Biological Processes. [PDF]

Pathophysiology
Narvaez Irizarry FY, Porter TR, Ramirez Serrano N, Kucheryavykh LY.   +3 more
europepmc   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Early Amyloid Formation and Neuroinflammatory Response in a Bigenic Mouse Model Expressing Human α-Synuclein and Aβ. [PDF]

Parkinsons Dis
Thakore R, Aldén M, Gustavsson N, Danielson L, Lins L, Sánchez JD, Arensburg AR, Paulus A, da Silva IAN, Skoryk V, Kayed R, Gouras GK, Deierborg T, Heuer A, Konings SC, Klementieva O.   +15 more
europepmc   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Alzheimer's disease and cerebrovascular biomarkers in relation to odor identification in a naturalistic clinical cohort. [PDF]

Alzheimers Res Ther
Oltra J, Ištvánfyová Z, Kalpouzos G, Ekström I, Hagman G, Kivipelto M, Laukka EJ.   +6 more
europepmc   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Considerations for the selection and phenotyping of mouse models for the study of Alzheimer's disease. [PDF]

STAR Protoc
Boyanova S, Katsouri L, Krupic J, Hair K, Wang SH, Wiseman FK.   +5 more
europepmc   +1 more source

Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience. [PDF]

Alzheimers Dement
Fonseca LM, Lila E, Shojaie A, Chhatwal J, Forlenza O, Beeri MS, Krinsky-McHale S, Cohen AD, Christian BT, Head E, Mapstone M, Handen B, Ances BM, Grabowski T, Chaytor NS, Zaman S, Alzheimer's Biomarkers Consortium‐ Down Syndrome (ABC‐DS) Investigators.   +16 more
europepmc   +1 more source